Zealand to present at upcoming Credit Suisse 2014 London Healthcare Conference

| Source: Zealand Pharma A/S

Copenhagen, 2014-02-20 16:02 CET (GLOBE NEWSWIRE) -- Investor News

No. 1/2014


Zealand to present at upcoming Credit Suisse 2014 London Healthcare Conference

  • The Company will be represented by Chief Executive Officer, David Solomon, and Chief Scientific Officer, Torsten Hoffmann


Copenhagen, 20 February 2014 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that the company will be presenting at the upcoming Credit Suisse 2014 London Healthcare Conference which takes place on Tuesday 4th – Wednesday 5th March at Credit Suisse’s Canary Wharf office in London, UK.

The concept of the conference is to provide investors with the opportunity to have detailed and focused one-on-one and small group meetings with senior management from a range of over 50 Global Healthcare companies.

At the conference, Zealand, represented by CEO, David Solomon, CSO Torsten Hoffmann and Vice President for Investor Relations, Hanne Leth Hillman, will be available for meetings on Wednesday 5th March. 




For further information, please contact:

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications

Tel: +45 5060 3689, email: hlh@zealandpharma.com


About Zealand

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia®) is approved in several countries, including Europe and Japan, and under regulatory review in a number of other countries globally. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA Cardiovascular outcome study. In February 2014, Sanofi started the Phase 3 clinical program for the Lantus®/Lyxumia® combination product (LixiLan). 

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. 

For further information: www.zealandpharma.com 

Follow us on Twitter @ZealandPharma